Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer

JCO Precis Oncol. 2023 Jul:7:e2300174. doi: 10.1200/PO.23.00174.

Authors

Sean R O'Neil¹, Garrett A Weber^{1

2}, Dustin A Deming³, Mark E Burkard³, Paraic A Kenny⁴, Craig S Richmond⁴, Benjamin M Parsons²

Affiliations

¹ Department of Medical Education, Gundersen Health System, La Crosse, WI.
² Department of Medical Oncology, Gundersen Health System, La Crosse, WI.
³ Department of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, WI.
⁴ Kabara Cancer Research Institute, Gundersen Health System, La Crosse, WI.

PMID: 37487149
DOI: 10.1200/PO.23.00174

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adaptor Proteins, Signal Transducing
Anilides
Crizotinib
Golgi Matrix Proteins
Humans
Neoplasms*
Protein-Tyrosine Kinases*
Proto-Oncogene Proteins

Substances

cabozantinib
Crizotinib
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Anilides
ROS1 protein, human
GOPC protein, human
Golgi Matrix Proteins
Adaptor Proteins, Signal Transducing